Table 13.
Variant persistence in HCV patients after treatment BID with 30 mg of DCV by population sequence
| Patient | Genotype | Time | RNA IU/ml | Substitution(s) (% frequency)a |
Additional mutation (% frequency) | |||
|---|---|---|---|---|---|---|---|---|
| M/L28 | Q/R30 | L31 | Y93 | |||||
| U | 1a | T0 | 2.0E+07 | WT | WT | WT | WT | |
| Day 14 | 1.8E+07 | T (∼7.5%) | E (∼70%), R (∼10%) | H58D (∼7.5%) | ||||
| Day 15 | 1.5E+07 | T (∼4%) | E (∼45%), H (∼5%), R (∼10%) | M (∼17.5%) | H58D (∼10%) | |||
| Day 21 | 1.8E+07 | T (∼2.5%) | E (∼80%), R (∼2.5%) | M (∼10%) | H58D (∼2.5%) | |||
| Day 28 | 2.5E+07 | T (∼12.5%) | E (∼45%), R (∼10%) | M (∼7.5%) | H58D (∼5%) | |||
| Day 42 | 3.2E+07 | T (∼10%) | E (∼62.5%), R (∼5%) | M (∼7.5%) | H58D (∼12.5%) | |||
| Day 116b | 2.3E+07 | T (∼5%) | E (∼25%), R (∼25%) | M (∼15%) | H (∼5%) | H58D (∼30%) | ||
| Day 182 | 2.7E+07 | T (∼7.5%), V (∼12.5%) | E (∼10%), H (∼10%), R (∼37.5%) | M (∼10%) | H (∼10%) | H58D (∼40%) | ||
| V | 1a | T0 | 4.3E+06 | H (∼100%) | H (∼45%) | |||
| Day 14 | 7.7E+04 | H (∼100%) | H (∼60%) | |||||
| Day 15 | 1.5E+05 | H (∼100%) | H (∼55%) | |||||
| Day 21 | 3.5E+05 | H (∼100%) | H (∼15%) | |||||
| Day 28 | 7.0E+05 | H (∼100%) | H (∼10%) | |||||
| Day 42 | 7.2E+06 | H (∼100%) | H (∼10%) | |||||
| Day 98 | 8.8E+06 | H (∼100%) | H (∼35%) | |||||
| Day 182 | 6.9E+06 | H (∼100%) | H (∼32.5%) | |||||
| W | 1b | T0 | 7.5E+06 | WT | WT | WT | WT | |
| Day 4 | 1.6E+03 | WT | WT | WT | WT | |||
| Day 14 | 5.0E+01 | ND | ND | ND | ND | |||
| Day 15 | 3.8E+01 | ND | ND | ND | ND | |||
| Day 21 | 6.2E+01 | ND | ND | ND | ND | |||
| Day 28 | 5.1E+02 | ND | ND | ND | ND | |||
| Day 42 | 1.1E+04 | I (∼27.5%), V (∼12.5%) | H (∼45%) | P32del (∼55%) | ||||
| Day 98 | 8.6E+06 | I (∼85%), V (∼10%) | H (∼95%) | F37L (∼10%), P32del (∼15%) | ||||
| Day 182 | 5.9E+06 | I (∼62.5%), V (∼12.5%) | H (∼72.5%) | F37L (∼2.5%), P32del (∼25%) | ||||
| X | 1b | T0 | 6.6E+06 | WT | WT | WT | WT | |
| Day 14 | <25 | ND | ND | ND | ND | |||
| Day 15 | <25 | ND | ND | ND | ND | |||
| Day 21 | 2.1E+02 | ND | ND | ND | ND | |||
| Day 28 | 2.8E+03 | I (∼72.5%), V (∼32.5%) | H (∼100%) | |||||
| Day 42 | 1.1E+06 | M (∼45%), V (∼55%) | H (∼100%) | |||||
| Day 98 | 4.6E+06 | I (∼70%), V (∼30%) | H (∼100%) | |||||
| Day 182 | 2.5E+06 | I (∼100%) | H (∼100%) | |||||
a
Frequencies are quantitative estimates of variants based on chromatograms from population sequencing (estimated from the average of two PCR products). “WT” indicates consensus with the WT. ND, not determined (HCV RNA < 1,000 IU/ml). Data for T0 to day 14 have been reported previously (3, 4).
b
Data derived from one PCR product.